SOUNDREEF
21.3.2024 20:10:32 CET | Business Wire | Press release
The European Court of Justice has issued a groundbreaking decision that opens the Italian copyright management market to Independent Management Entities. Soundreef, a leading independent management entity in Europe, celebrates this significant victory for the rights of authors, composers, and publishers to choose their representation in the copyright management sector.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321014981/en/
Davide d'Atri - Soundreef CEO (Photo: Business Wire)
The Court ruling reads:
“In its judgment, the Court replies that, in so far as the national legislation at issue does not allow independent management entities established in another Member State to provide their copyright management services in Italy, it constitutes a restriction on the freedom to provide services. Although that restriction may in principle be justified by the overriding objective of protecting intellectual property rights, it is not proportionate, as it generally and absolutely precludes any independent management entity established in another Member State from carrying out its activity in the market concerned. The Court points out that measures that are less restrictive of the freedom to provide services might enable the objective to be attained. Consequently, the Court finds that the Italian legislation at issue is not compatible with EU law.”
This decision highlights the importance of a liberalized market that welcomes private entities, promoting innovation and offering rightsholders improved management options.
Soundreef has played a crucial role in supporting this change over the last 10 years, together with industry partners, to ensure a more efficient, fair, and forward-looking copyright ecosystem. Soundreef is also the first independent management entity in Europe with a fully operational collection network, ready to leverage this new opportunity to enhance its services to authors, composers, and publishers.
Soundreef already represents over 43,000 songwriters and publishers globally, with 26,000 hailing from Italy. This includes stars such as Gigi D’Alessio, J-AX, Laura Pausini, Ultimo, Alejandro Sanz, and Sfera Ebbasta; heritage and contemporary writers like Giancarlo Bigazzi, Maurizio Fabrizio, Takagi & Ketra, and Federica Abbate; as well as some of the most important Italian rap artists and film and TV composers. In addition, SESAC Performing Rights has chosen Soundreef to represent its extensive repertoire in Italy, effective January 1, 2024. Founded in 1930, SESAC Performing Rights currently licenses the public performance of thousands of chart-topping songs on behalf of its top-tier affiliated songwriters and music publishers, which include such familiar names as Bob Dylan, Neil Diamond, Adele, Jack Harlow, Ariana Grande, Disclosure, Zac Brown, Rosanne Cash, Lee Brice, Margo Price, Nicky Jam, Blanco Brown, and many more. SESAC has also long represented the music on some of TV’s biggest shows including Grey’s Anatomy, How I Met Your Mother, A Million Little Things, Manifest, Dateline NBC, Dr. Phil, Seinfeld, and Modern Family, and is the PRO of choice among many of Hollywood’s most sought-after film and television composers including Christophe Beck, Danny Lux, The Newton Brothers, John Ehrlich, Gabriel Mann, Lili Haydn, and Guillermo Brown among others.
E-Lex is, from the very beginning, the law firm that assisted Soundreef in the main disputes in the field of copyright and copyright management. The team, initially led by Guido Scorza (now a member of the Italian Data Protection Authority), is now composed by Professor Giovanni Maria Riccio, the lawyer Adriana Peduto, partners in the firm, and the lawyer Dario Malandrino.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321014981/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 09:20:00 CEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
